Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres
Open Access
- 18 August 2015
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 1-10
Abstract
The STAT3 transcription factor is a major intracellular signaling protein and is frequently dysregulated in the most common and lethal brain malignancy in adults, glioblastoma multiforme (GBM). Activation of STAT3 in GBM correlates with malignancy and poor prognosis. The phosphorylating signal transducer JAK2 activates STAT3 in response to cytokines and growth factors. Currently there are no JAK-STAT pathway inhibitors in clinical trials for GBM, so we sought to examine the anti-GBM activity of SAR317461 (Sanofi-Aventis), a newer generation, highly potent JAK2 inhibitor that exhibits low toxicity and good pharmacokinetics. SAR317461 was initially approved for patient testing in the treatment of primary myelofibrosis (PMF), and has shown activity in preclinical models of melanoma and pulmonary cancer, but has not been tested in GBM. We hypothesized that a potent small molecule JAK2 inhibitor could overcome the heterogeneous nature of GBM, and suppress a range of patient derived GBM tumorsphere lines and immortalized GBM cell lines. We treated with SAR317461 to determine IC50 values, and using Western blot analysis we asked whether the response was linked to STAT3 expression. Western blot analysis, FACS, and cell viability studies were used to identify the mechanism of SAR317461 induced cell death. We report for the first time that the JAK2 inhibitor SAR317461 clearly inhibited STAT3 phosphorylation and had substantial activity against cells (IC50 1–10 µM) from 6 of 7 different patient GSC derived GBM tumorsphere lines and three immortalized GBM lines. One patient GSC derived line did not constitutively express STAT3 and was more resistant to SAR317461 (IC50 ≈25 µM). In terms of mechanism we found cleaved PARP and clear apoptosis following SAR317461. SAR317461 also induced autophagy and the addition of an autophagy inhibitor markedly enhanced cell killing by SAR317461. We conclude that SAR317461 potently inhibits STAT3 phosphorylation and that it has significant activity against those GBM cells which express activated STAT3. Further studies are warranted in terms of the potential of SAR317461 as single and combined therapy for selectively treating human patients afflicted with GBMs expressing activation of the JAK2-STAT3 signaling axis.Keywords
This publication has 37 references indexed in Scilit:
- SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival AnalysisPLOS ONE, 2013
- LPS-induced release of IL-6 from glia modulates production of IL-1β in a JAK2-dependent mannerJournal of Neuroinflammation, 2012
- Inhibition of JAK2 Signaling by TG101209 Enhances Radiotherapy in Lung Cancer ModelsJournal of Thoracic Oncology, 2011
- Elevated invasive potential of glioblastoma stem cellsBiochemical and Biophysical Research Communications, 2011
- Characterization of a human tumorsphere glioma orthotopic model using magnetic resonance imagingJournal of Neuro-Oncology, 2011
- TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cellsAmerican Journal of Hematology, 2010
- Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United StatesClinical Cancer Research, 2010
- A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cellsMolecular Cancer, 2010
- Deregulation of a STAT3-Interleukin 8 Signaling Pathway Promotes Human Glioblastoma Cell Proliferation and InvasivenessJournal of Neuroscience, 2008
- Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesisOncogene, 2002